February 13, 2026 5:03pm

CPI report is a reprieve for investors distraught by Ai share pricing interruptus in the market and sector

Right yet again, after again, another again yet with another etc. …

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Pre-open Indications: 2 Hits and 2 Miss

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

TGIF, next week will be a shortened trading week, as the market will be closed Monday for Presidents’ Day.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

 

RMi Pre-opening: Yet another econs, CPI … https://www.regmedinvestors.com/articles/14312

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Friday: The Dow closed UP +48.95 points or +0.10%, the S&P closed UP +3.41 points or +0.05% while the Nasdaq closed DOWN -50.4777 points or -0.22%

  • Theme of the session: CPI came in slightly lighter than expected

Friday’s (my) 40-company covered sector’s advance/decline line opened positive with 33 incliners, 4 decliners and 3 flats, ending with a positive close of 24 incliners, 14 decliners and 2 flats

  • Welcoming the ups after sessions of drifting with buying the dips was time oriented  

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Consumer price index (CPI) which measures the costs for goods and services in the U.S. economy rose 0.2% in January, reflecting a gain of 2.4% on an annualized basis. Excluding volatile food and energy prices, core CPI came in line with expectations at 0.3% on the month and 2.5% year over year.
  • The inflation gauge was expected to show a 0.3% increase on a month-over-month basis and a 2.5% advance from a year earlier.

The CBOE Fear (VIX) index, Friday closed at 20.69, after Thursday’s 20.90, after Wednesday’s 17.71, Tuesday’s 17.23, Monday’s 17.44 and last Friday’s 17.75

Metrics: Friday …

  • The RUT was up +30.87 points or +1.18%,
  • The XLV was up +1.67 points or +1.07%,
  • The NBI was up +26.57 points or +0.97%;
  • The XBI was down -0.33 points or -0.27%
  • The IWM was up +3.39 or +1.31%;
  • The IBB was up +1.86 points or +1.09%,
  • The VIX was down -0.13 points or -0.62% at to 20.69

 

Q1/26 February – 6 negative and 4 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Friday Closing UP (10 of 24)

  • Vertex (VRTX +$26.45 after Thursday’s +$3.78 after Wednesday’s -$2.24, Tuesday’s -$7.39 and Monday’s -$7.05),
  • Alnylam Pharmaceuticals (ALNY +$5.92 after Thursday’s -$13.27 after Wednesday’s -$1.23 after Tuesday’s +$2.98 after Monday’s -$8.16),
  • CRISPR Therapeutics (CRSP +$4.14 after Thursday’s +$0.61),
  • Moderna (MRNA +$2.12),
  • Vericel (VCEL +$1.99),
  • Arrowhead Pharmaceuticals (ARWR +$ after Thursday’s +$0.83 after Wednesday’s -$1.37, Tuesday’s +$0.32 and Monday’s -$1.88),
  • Supernus Therapeutics (SUPN +$1.44 after Thursday’s -$1.49 after Wednesday’s +$0.13),
  • Beam Therapeutics (BEAM +$0.99 after Thursday’s +$0.94 and Wednesday’s -$0.96),
  • BioLife Solutions (BLFS +$0.65 after Thursday’s -$0.67),
  • AxoGen (AXGN +$0.62 after Thursday’s -$1.29 after Wednesday’s -$0.61 after Tuesday’s +$0.58 after Monday’s -$1.00),

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Thursdday's $0.00, Wednesday’s $0.00, Tuesday’s +$0.10 <with 660 shares> and Monday’s $0.00),

Friday’s Closing DOWN (10 of 14): 

  • Ultragenyx Pharmaceuticals (RARE -$2.98),
  • IQIA Holdings (IQV -$1.94 after Thursday’s -$8.26 after Wednesday’s -$5.29 after Tuesday’s -$10.22 after Monday’s +$5.27),
  • uniQure NV (QURE -$1.87 after Thursday’s -$1.74 after Wednesday’s -$0.60 after Tuesday’s -$1.34 after Monday’s +$0.40),
  • Capricor Therapeutics (CAPR -$1.22),
  • Ionis Pharmaceuticals (IONS -$1.18 after Thursday’s -$2.57 after Wednesday’s -$0.06 after Tuesday’s -$0.50 after Monday’s -$1.71),
  • Dyne Therapeutics (DYN -$0.46 after Thursday’s -$0.68),
  • Regenxbio (RGNX -$0.36),
  • Mesoblast (MESO -$0.22 after Thursday’s -$1.41 after Wednesday’s +$0.31 after Tuesday’s +$1.21 after Monday’s +$0.83),
  • Wave Life Sciences (WVE -$0.12),
  • Lenz Therapeutics (LENZ -$0.09),

 

The Bottom Line: More of the … WHY

A volatile week … battered by fears that AI will disrupt business models.

  • Indexes lost steam heading into the close on Friday to post weekly losses digesting a cooler-than-expected inflation reading.

The S&P 500 inched just above the flatline, the Dow closed up while the Nasdaq fell.

  • Techs got pummeled yet again, with all 7 of the "Magnificent Seven" mega-caps finishing lower; after a week of heavy selling as fears about AI disruption spilled into "old economy" names previously seen as a safe alternative to AI-tied stocks.

 

Earnings release dates:

  • Tuesday - 2/24 – AxoGen (AXGN)
  • Wednesday – 2/25 – Ionis Pharmaceuticals (IONS) and Sarepta Theoretics (SRPT)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 2nd week

  • 2/13 - Friday closed positive with 24 incliners, 14 decliners and 2 flats
  • 2/12 – Thursday closed negative with 7 incliners, 33 decliners and 2 flats
  • 2/11 - Wednesday closed negative with 12 incliners, 25 decliners and 3 flats
  • 2/10 - Tuesday closed negative with 19 incliners, 20 decliners and 1 flat
  • 2/9 -Monday closed positive with 23 incliners, 14 decliners and 3 flats

February – 1st week

  • 2/6 – Friday closed positive with 35 incliners, 5 decliners and 0 flat
  • 2/5 -Thursday closed negative with 2 incliners, 36 decliners and 2 flats
  • 2/4 -Wednesday closed negative with 10 incliners, 29 decliners and 1 flat               
  • 2/3 -Tuesday closed negative with 18 incliners, 21 decliners and 1 flat      
  • 2/2 -Monday closed positive with 29 incliners, 10 decliners and 1 flat

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Friday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP) 
  • Thursday: Vertex (VRTX), Beam Therapeutics (BEAM) and Arrowhead Pharmaceuticals (ARWR)
  • Wednesday: BioNTech (BNTX), Mesoblast (MESO) and Entrada Therapeutics (TRDA)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Mesoblast (MESO) and AxoGen (AXGN)
  • Monday: IQIA Holdings (IQV), BioNTech (BNTX) and Mesoblast (MESO)

The worst three (3) in the session: Losers

  • Friday: Ultragenyx Pharmaceuticals (RARE), IQIA Holdings (IQV) and uniQure NV (QURE)
  • Thursday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and BioNTech (BNTX)
  • Wednesday: IQIA Holdings (IQV), Vertex (VRTX) and Moderna (MRNA) 
  • Tuesday: IQIA Holdings (IQV), Vertex (VRTX) and Regenxbio (RGNX)
  • Monday: BioNTech (BNTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.